Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Horizon rapeutics

Amgen to buy Horizon Therapeutics in $26.4B deal

Horizon Therapeutics, whose U.S. headquarters is in Deerfield, is a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases.

Chicago Sun-Times

Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analyst Ratings for Horizon Therapeutics

Horizon Therapeutics (NASDAQ:HZNP) has observed the following analyst ratings within the last quarter:

4 Analysts Have This to Say About Horizon Therapeutics

Horizon Therapeutics (NASDAQ:HZNP) has observed the following analyst ratings within the last quarter:

Horizon Therapeutics Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Horizon Therapeutics (NASDAQ:HZNP) earned $204.26 million, a 17.95% increase from the preceding quarter. Horizon Therapeutics's sales decreased to $885.25 million, a 12.7% change since Q4.

Emotional reunion in store for Padraig Harrington and Peter McEnery at the Horizon Irish Open

Having played together in at the Pro-Am in 2010, the pair will do so again at Mount Juliet at the end of June to mark Make-A-Wish Ireland's six-year link-up with the Horizon Irish Open

inkl

Read news from The Economist, FT, and more,
with one subscription

Horizon Therapeutics: Q1 Earnings Insights

Horizon Therapeutics: Q1 Earnings Insights

Horizon Therapeutics (NASDAQ:HZNP) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Will Investors Notice Exciting Sign On Horizon Therapeutics's Chart?

Will Investors Notice Exciting Sign On Horizon Therapeutics's Chart?

If history is any guide, there may be good fortune ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Horizon Therapeutics Earnings Perspective: Return On Capital Employed

Horizon Therapeutics Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Horizon Therapeutics (NASDAQ:HZNP) posted Q4 earnings of $173.18 million, an increase from Q3 of 46.97%. Sales dropped to $1.01 billion, a 2.22% decrease between quarters.

People

Padraig Harrington

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Alnylam Pharmaceuticals

Essex Property Trust

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Autoimmune Disease

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play